Development and validation of a specific and sensitive HPLC-ESI-MS method for quantification of lysophosphatidylinositols and evaluation of their levels in mice tissues
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 126, 132-140
Abstract
No abstract availableKeywords
Funding Information
- Valentin Mutemberezi for his helpful suggestions
This publication has 33 references indexed in Scilit:
- L-α-Lysophosphatidylinositol meets GPR55: a deadly relationshipTrends in Pharmacological Sciences, 2011
- The putative cannabinoid receptor GPR55 promotes cancer cell proliferationOncogene, 2010
- Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugsBritish Journal of Cancer, 2010
- The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferationOncogene, 2010
- The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERKOncogene, 2010
- Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): Possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- A role for L‐α‐lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cellsBritish Journal of Pharmacology, 2010
- Improved method for the quantification of lysophospholipids including enol ether species by liquid chromatography-tandem mass spectrometryJournal of Lipid Research, 2010
- Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferationOncogene, 1998
- Lysophosphatidylinositol, but not lysophosphatidic acid, stimulates insulin releaseBiochemical and Biophysical Research Communications, 1986